Transbronchial Lung Cryobiopsy in Patients with Interstitial Lung Disease: A Systematic Review

Kheir, Fayez; Becerra, Juan Pablo Uribe; Bissell, Brittany D; Ghazipura, Marya; Herman, Derrick; Hon, Stephanie; Hossain, Tanzib; Khor, Yet H.; Knight, Shandra L; Kreuter, Michael; Macrea, Madalina; Mammen, Manoj J.; Martínez, Fernando J.; Poletti, Venerino; Troy, Lauren; Raghu, Ganesh; Wilson, Kevin C.

doi:10.1513/annalsats.202102-198oc

Cited by 58 publications

(39 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…G.R. Scott Budinger (Northwestern University, IL, USA) presented current data concerning COVID-19 patients at imminent risk of dying due to ARDS who had received lung transplantations [1][2][3][4]. He started by saying that "patients with COVID-19-associated ARDS who received lung transplants had similar outcomes compared with transplant patients without COVID-19, despite modestly increased early post-op complications.…”

Section: Lung Transplantation After Covid-19associated Ardsmentioning

confidence: 99%

“…In the retrospective study, Prof. Budinger mostly focused on the case series including 102 patients who underwent a lung transplant at Northwestern Memorial Hospital between January 2020 and September 2021, including 30 patients who had COVID-19-associated ARDS [3]. While rates of transplant complications and length of stays in intensive care units were both higher in the group with COVID-19, patient survival in both groups was not significantly different.…”

Section: Lung Transplantation After Covid-19associated Ardsmentioning

confidence: 99%

“…In another session, Dr Bradley Chipps (Capital Allergy & Respiratory Disease Center, CA, USA) presented the results of the phase 3 DENALI trial (NCT03847896) [3]. DENALI was a randomised, double-blind, placebo-controlled, multicentre, parallel-group trial.…”

Section: Mandala and Denali Pattern Success For Albuterol-budesonide ...mentioning

confidence: 99%

“…In a related talk, Prof. Ian Pavord (University of Oxford, UK) and colleagues used data from the Liberty Asthma QUEST study (NCT02414854) in order to identify biomarkers that may predict risk of lung function decline and response to dupilumab [3]. Multivariate regression analysis identified covariates that predicted lung function decline in placebo and dupilumab arms, with patients stratified by baseline exhaled nitric oxide (FeNO) levels and blood eosinophil levels.…”

Section: Type 2 Asthma In Children Managed By Dupilumab Despite Atopi...mentioning

confidence: 99%

“…A diagnosis of UIP via biopsy is based on a set of histopathological features. Although transbronchial lung cryobiopsy (TBLC) is more likely to detect a probable UIP pattern than a definite UIP pattern compared with surgical lung biopsy (SLB), a novel systematic review has been published since the development of the IPF guidelines of 2018, demonstrating that TBLC may be a valid alternative to SLB in experienced centres [3,4]. Therefore, the committee made the conditional recommendation that TBLC may be an alternative to SLB when making a histopathological diagnosis in patients with ILD.…”

Section: New Guidelines For Ipf and Ppfmentioning

confidence: 99%

See 4 more Smart Citations

Medicom Conference Report ATS 2022

2022

View full text Add to dashboard Cite

show abstract

Section: Lung Transplantation After Covid-19associated Ardsmentioning

confidence: 99%

Section: Lung Transplantation After Covid-19associated Ardsmentioning

confidence: 99%

Section: Mandala and Denali Pattern Success For Albuterol-budesonide ...mentioning

confidence: 99%

Section: Type 2 Asthma In Children Managed By Dupilumab Despite Atopi...mentioning

confidence: 99%

Section: New Guidelines For Ipf and Ppfmentioning

confidence: 99%

See 3 more Smart Citations

Medicom Conference Report ATS 2022

2022

View full text Add to dashboard Cite

show abstract

Interstitial Lung Disease

Maher

2024

JAMA

View full text Add to dashboard Cite

ImportanceInterstitial lung disease (ILD) consists of a group of pulmonary disorders characterized by inflammation and/or fibrosis of the lung parenchyma associated with progressive dyspnea that frequently results in end-stage respiratory failure. In the US, ILD affects approximately 650 000 people and causes approximately 25 000 to 30 000 deaths per year.ObservationsThe most common forms of ILD are idiopathic pulmonary fibrosis (IPF), which accounts for approximately one-third of all cases of ILD, hypersensitivity pneumonitis, accounting for 15% of ILD cases, and connective tissue disease (CTD), accounting for 25% of ILD cases. ILD typically presents with dyspnea on exertion. Approximately 30% of patients with ILD report cough. Thoracic computed tomography is approximately 91% sensitive and 71% specific for diagnosing subtypes of ILDs such as IPF. Physiologic assessment provides important prognostic information. A 5% decline in forced vital capacity (FVC) over 12 months is associated with an approximately 2-fold increase in mortality compared with no change in FVC. Antifibrotic therapy with nintedanib or pirfenidone slows annual FVC decline by approximately 44% to 57% in individuals with IPF, scleroderma associated ILD, and in those with progressive pulmonary fibrosis of any cause. For connective tissue disease–associated ILD, immunomodulatory therapy, such as tocilizumab, rituximab, and mycophenolate mofetil, may slow decline or even improve FVC at 12-month follow-up. Structured exercise therapy reduces symptoms and improves 6-minute walk test distance in individuals with dyspnea. Oxygen reduces symptoms and improves quality of life in individuals with ILD who desaturate below 88% on a 6-minute walk test. Lung transplant may improve symptoms and resolve respiratory failure in patients with end-stage ILD. After lung transplant, patients with ILD have a median survival of 5.2 to 6.7 years compared with a median survival of less than 2 years in patients with advanced ILD who do not undergo lung transplant. Up to 85% of individuals with end-stage fibrotic ILD develop pulmonary hypertension. In these patients, treatment with inhaled treprostinil improves walking distance and respiratory symptoms.Conclusions and RelevanceInterstitial lung disease typically presents with dyspnea on exertion and can progress to respiratory failure. First-line therapy includes nintedanib or pirfenidone for IPF and mycophenolate mofetil for ILD due to connective tissue disease. Lung transplant should be considered for patients with advanced ILD. In patients with ILD, exercise training improves 6-minute walk test distance and quality of life.

show abstract

Pneumologische Diagnostik – Methoden und Ablauf

Kalsdorf,

Stellmacher

2024

Pathologie Nicht-Neoplastischer Lungenerkrankungen

View full text Add to dashboard Cite

Transbronchial Lung Cryobiopsy in Patients with Interstitial Lung Disease: A Systematic Review

Cited by 58 publications

References 46 publications

Medicom Conference Report ATS 2022

Medicom Conference Report ATS 2022

Interstitial Lung Disease

Pneumologische Diagnostik – Methoden und Ablauf

Contact Info

Product

Resources

About